HARVARD BIOSCIENCE INC — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Harvard Bioscience (market cap ~$18.2M) completed a $40M debt refinancing with BroadOak Capital Partners consisting of $10M Term Loan A, $22.5M Term Loan B (converts at $10/share), and $7.5M Term Loan C. The refinancing extends maturity to December 2029, reduces annual debt service by $3M, and includes BroadOak board seat and 200K warrant grant. Company appointed new CEO John Duke (July 2025) and permanent CFO Mark Frost (March 2026), and announced Project Viking: consolidating Holliston, MA plant by Q1 2027, targeting $3M adjusted EBITDA improvement in 2027 and $4M ongoing. FY26 guidance raised to 3-5% revenue growth; adjusted EBITDA margin guided 57-59%.
Why this rating
Refinancing at ~$40M (2.2x company market cap) materially strengthens balance sheet relative to tiny size; $3M annual debt savings and $7M cumulative 2027-28 EBITDA uplift represent 37-50% of recent adjusted EBITDA. New leadership and strategic refocus are positive. However, higher blended interest rates (12.8%-12.5% on Term B/C) and dilutive conversion terms create headwinds. Execution risk on plant closure substantial for small firm.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.